121 related articles for article (PubMed ID: 38536058)
1. Acute and long-term results of percutaneous coronary intervention of bifurcation lesions with the dedicated Bioss Lim C stent: the Italian BIfurcation Observational Spontaneous Study (IBIOSS).
Briguori C; Capodanno D; Contarini M; Donahue ME; Evola S; Garro N; Greco F; LA Manna A; Murè P; Nicosia A; Migliore G; Sacchetta G; Signore N; Tamburino C; Vizzari G; Biondi-Zoccai G
Minerva Med; 2024 Apr; 115(2):171-177. PubMed ID: 38536058
[TBL] [Abstract][Full Text] [Related]
2. First-in-man study of paclitaxel-eluting stent BiOSS (Bifurcation Optimisation Stent System) dedicated for coronary bifurcation stenoses: three months results.
Gil RJ; Vassiliev D; Michałek A; Kern A; Formuszewicz R; Dobrzycki S; Lesiak M; Wójcik J; Kardaszewicz P; Lekston A
Kardiol Pol; 2012; 70(1):45-52. PubMed ID: 22267425
[TBL] [Abstract][Full Text] [Related]
3. Dedicated bifurcation stents or regular drug eluting stents in distal left main stenosis: A retrospective study.
Kern A; Gil RJ; Bojko K; Rzeszowski B; Bednarski K; Górny J; Bil J
Cardiol J; 2018; 25(2):188-195. PubMed ID: 28714525
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of a dedicated bifurcation stent system.
Sivalingam J; Mazhar MW; Chaddad RA; Fouladvand F; Cortese B
Cardiovasc Revasc Med; 2024 Feb; 59():21-26. PubMed ID: 37666716
[TBL] [Abstract][Full Text] [Related]
5. 5-Year clinical follow-up of the COBRA (complex coronary bifurcation lesions: Randomized comparison of a strategy using a dedicated self-expanding biolimus A9-eluting stent vs. a culotte strategy using everolimus-eluting stents) study.
Bennett J; Adriaenssens T; McCutcheon K; Dens J; Desmet W; Sinnaeve P; Vrolix M; Dubois C
Catheter Cardiovasc Interv; 2018 Nov; 92(6):E375-E380. PubMed ID: 29536609
[TBL] [Abstract][Full Text] [Related]
6. First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C® - three-month results.
Gil RJ; Bil J; Kern A; Pawłowski T
Kardiol Pol; 2018; 76(2):464-470. PubMed ID: 29192951
[TBL] [Abstract][Full Text] [Related]
7. Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies.
Gil RJ; Bil J; Kern A; Iñigo-Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Mehran R
Cardiovasc Ther; 2020; 2020():6760205. PubMed ID: 32411301
[TBL] [Abstract][Full Text] [Related]
8. Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIM® stent: the randomised, multicentre, open-label, controlled POLBOS II trial.
Gil RJ; Bil J; Grundeken MJ; Kern A; Iñigo Garcia LA; Vassilev D; Pawłowski T; Formuszewicz R; Dobrzycki S; Wykrzykowska JJ; Serruys PW
EuroIntervention; 2016 Dec; 12(11):e1404-e1412. PubMed ID: 26600564
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
[TBL] [Abstract][Full Text] [Related]
10. Regular Drug-Eluting Stent vs Dedicated Coronary Bifurcation BiOSS Expert Stent: Multicenter Open-Label Randomized Controlled POLBOS I Trial.
Gil RJ; Bil J; Džavík V; Vassilev D; Kern A; Formuszewicz R; Zalewska-Adamiec M; Dobrzycki S
Can J Cardiol; 2015 May; 31(5):671-8. PubMed ID: 25828372
[TBL] [Abstract][Full Text] [Related]
11. The approach to coronary bifurcation treatment and its outcomes in Poland: The single center experience.
Kern A; Gil RJ; Bojko K; Rzeszowski B; Jalali R; Górny J; Bil J
Cardiol J; 2017; 24(6):589-596. PubMed ID: 28541601
[TBL] [Abstract][Full Text] [Related]
12. First-in-man study of dedicated bifurcation sirolimus-eluting stent: 12-month results of BiOSS LIM® Registry.
Gil RJ; Bil J; Vassiliev D; Iñigo Garcia LA
J Interv Cardiol; 2015 Feb; 28(1):51-60. PubMed ID: 25689548
[TBL] [Abstract][Full Text] [Related]
13. Sirolimus-eluting BiOSS LIM dedicated bifurcation stent in the treatment of unprotected distal left main stenosis.
Briguori C; Visconti G; Golino M; Focaccio A; Signoriello G
Catheter Cardiovasc Interv; 2019 Sep; 94(3):323-331. PubMed ID: 30773807
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dedicated BIOSS bifurcation stents with regular drug-eluting stents for coronary artery bifurcated lesions: Pooled analysis from two randomized studies.
Gil RJ; Bil J; Kern A; Iñigo Garcia LA; Formuszewicz R; Dobrzycki S; Vassilev D; Segiet A
Cardiol J; 2018; 25(3):308-316. PubMed ID: 28840591
[TBL] [Abstract][Full Text] [Related]
15. 12-month intravascular ultrasound observations from BiOSS® first-in-man studies.
Gil RJ; Bil J; Costa RA; Gil KE; Vassiliev D
Int J Cardiovasc Imaging; 2016 Sep; 32(9):1339-1347. PubMed ID: 27314841
[TBL] [Abstract][Full Text] [Related]
16. The Randomized, Multicenter, Open-Label, Controlled POLBOS 3 Trial Comparing Regular Drug-Eluting Stents and the Sirolimus-Eluting BiOSS LIM C Dedicated Coronary Bifurcation Stent: Four-Year Results.
Gil RJ; Kern A; Bojko K; Gziut-Rudkowska A; Vassilev D; Bil J
Biomedicines; 2024 Apr; 12(5):. PubMed ID: 38790900
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system.
Triantafyllis AS; Bennett J; Pagourelias E; McCutcheon K; Adriaenssens T; Sinnaeve PR; Desmet W; Dubois C
Cardiol J; 2018; 25(4):470-478. PubMed ID: 29240962
[TBL] [Abstract][Full Text] [Related]
18. Dedicated paclitaxel-eluting bifurcation stent BiOSS® (bifurcation optimisation stent system): 12-month results from a prospective registry of consecutive all-comers population.
Gil RJ; Vassilev D; Michalek A; Kern A; Formuszewicz R; Dobrzycki S; Wójcik J; Lesiak M; Kardaszewicz P; Lekston A
EuroIntervention; 2012 Jul; 8(3):316-24. PubMed ID: 22829507
[TBL] [Abstract][Full Text] [Related]
19. Impact of the complexity of bifurcation lesions treated with drug-eluting stents: the DEFINITION study (Definitions and impact of complEx biFurcation lesIons on clinical outcomes after percutaNeous coronary IntervenTIOn using drug-eluting steNts).
Chen SL; Sheiban I; Xu B; Jepson N; Paiboon C; Zhang JJ; Ye F; Sansoto T; Kwan TW; Lee M; Han YL; Lv SZ; Wen SY; Zhang Q; Wang HC; Jiang TM; Wang Y; Chen LL; Tian NL; Cao F; Qiu CG; Zhang YJ; Leon MB
JACC Cardiovasc Interv; 2014 Nov; 7(11):1266-76. PubMed ID: 25326748
[TBL] [Abstract][Full Text] [Related]
20. Impact of kissing balloon inflation on the main vessel stent volume, area, and symmetry after side-branch dilation in patients with coronary bifurcation lesions: a serial volumetric intravascular ultrasound study.
Rahman S; Leesar T; Cilingiroglu M; Effat M; Arif I; Helmy T; Leesar MA
JACC Cardiovasc Interv; 2013 Sep; 6(9):923-31. PubMed ID: 23954062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
